Q4 2025 Earnings Call March 12, 2026 4:30 PM EDTCompany ParticipantsJennie WillsonJacqueline Shea - CEO, President ...
BACKGROUND: Aortic valve calcification increases leaflet stiffness and contributes to the development of calcific aortic valve disease. The molecular and cellular mechanisms underlying calcification ...
MedPage Today on MSN
Dual immunotherapy and liver perfusion delays progression in uveal melanoma
Ipilimumab-nivolumab also linked with better survival but more toxicity in small study ...
SAN FRANCISCO -- Adjuvant durvalumab (Imfinzi) and tremelimumab (Imjudo) improved disease-free survival (DFS) in a phase III trial of resectable renal cell carcinoma (RCC), but researchers here said ...
Egle Therapeutics SAS (Egle), a clinical-stage biotechnology company pioneering precision medicines that modulate regulatory ...
2月23日，和铂医药公告称，公司与SOLSTICE ONCOLOGY就HBM4003订立授权协议及股权合作协议。据此，公司同意向Solstice Oncology授予独家授权，以在大中华区以外地区开发及商业化其临床阶段组合资产HBM4003。根据该等协议的条款，公司有资格获得价值超过1.05亿美元的前期 ...
智通财经APP获悉，和铂医药-B(02142)早盘涨超8%，截至发稿，涨7.92%，报13.21港元，成交额2179.47万港元。 消息面上，2月23日，和 ...
本文系基于公开资料撰写，仅作为信息交流之用，不构成任何投资建议。 随着2025年诺贝尔生理学或医学奖授予三位专注于调节性T细胞（Treg细胞）研究的免疫学家，曾一度被市场边缘化的CTLA-4靶点再度成为生物医药业界的关注焦点。在此行业风口到来之际，全球 ...
格隆汇2月16日丨基石药业-B (02616.HK)发布公告，公司核心资产CS2009 (PD-1/VEGF/CTLA-4三特异性抗体)用于晚期实体瘤的II期新药临床试验 (IND)申请已经获得美国食品药品监督管理局 (FDA)批准。根据披露，CS2009用于晚期实体瘤的II期IND申请获FDA批准，标志着这一创新免疫疗法的全球开发取得重要进展。该II期 ...
CS2009 (PD-1/VEGF/CTLA-4 trispecific antibody) has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) to initiate a Phase II clinical trial in patients ...
CS2009 (PD-1/VEGF/CTLA-4 trispecific antibody) has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) to initiate a Phase II clinical trial in patients ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果